Yimmugo (immune globulin intravenous, human-dira) / Grifols, Kedrion - LARVOL DELTA

Antibody Titers against several Viral and Bacterial Agents in BT595 a novel 10% IgG Preparation (ACAAI 2025) - P3 | "Mean half-life ranged from 18.6 to 32.4 days in the Q3W group and from 22.1 to 30.3 days in the Q4W group. Conclusion Both schedule groups provide relevant concentrations of the 6 analyzed antigen-specific IgGs needed to effectively defend infection related diseases."

Cytomegalovirus Infection • Hepatitis B • Hepatology • Immunology • Infectious Disease • Inflammation • Influenza • Measles • Pediatrics • Pneumococcal Infections • Primary Immunodeficiency • Respiratory Diseases • Tetanus

Levels of IgG Subclasses 1-4 in a Clinical Trial for BT595 (10% IVIg) (ACAAI 2025) - P3 | "Consistent with total IgG data, mean concentration and C max was higher in the Q3W than in the Q4W group for each IgG subclass, while the AUC over the dosing interval (AUC tau ) was lower in the Q3W group due to the 7-day shorter dosing interval. Conclusion The patients achieved sufficient concentrations of all IgG subclasses in normal physiological proportions needed to effectively prevent infections."

Clinical • Infectious Disease

Treatment of a Complex Case of Scleromyxedema Using a Novel Intravenous Immunoglobulin Preparation. (PubMed, Case Rep Dermatol) - "After transitioning to Yimmugo®, the patient reported an improved quality of life. Further follow-up is essential to conclusively evaluate effectiveness and tolerability of this novel IVIg preparation."

Journal • Chronic Kidney Disease • Fatigue • Monoclonal Gammopathy • Pain • Renal Disease